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Abstract: The adhesion molecule αvβ3 integrin plays an important role in tumor development 
and metastases. We demonstrated the specificity of the probe to αvβ3 integrin with transmis-
sion electron microcopy (TEM) and magnetic resonance imaging (MRI). The in vivo targeting 
behavior of the probe was examined in 2 tumor models with different αvβ3 expression patterns 
by a 3.0T MRI scanner. MR imaging showed that R2* pseudo-color pictures of A549 lung 
cancer tumor was different from that of 3LL lung cancer. For A549 tumor, an homogeneous 
decrease of signal intensity was observed throughout the tumor, which was more evident in 
the periphery or central areas. Histological studies revealed that αvβ3 integrin was expressed 
both on the tumor vessel and tumor cells for A549 tumor. Our findings indicated that it was 
possible to noninvasively characterize the different αvβ3 expression pattern in lung cancers 
with arginine-glycine-aspartic acid (RGD) peptide conjugated ultra-small superparamagnetic 
iron oxide nanoparticles (RGD-USPIO) using a clinical 3.0T MR scanner. Nevertheless, the 
way of imaging targeting presentation of the probe differed in tumors with different αvβ3 
expression patterns.
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Introduction
Angiogenesis, as a fundamental step in the development, progression and metastasis 
of tumors, has become one of the most important and popular fields of tumor research 
in recent years, and a breakthrough is most likely in the future.1 Visual and quantita-
tive studies of neovascularization are beneficial to early diagnosis of tumors and help 
whole-course monitoring of tumor neovascularization and evaluation of therapeutic 
effects during clinical use of angiogenesis antagonists for tumor treatment.2 Although 
many angiogenesis antagonists have been used in clinical trials,3 we are convinced that 
the success of this therapeutic approach is bound to be accompanied by the develop-
ment of a highly specific marker for angiogenesis and effective imaging techniques to 
determine the optimal therapeutic dosage at morphological, functional and molecular 
levels and monitor patient’s therapeutic responses.4 We are sure that the study of 
angiogenesis imaging will play an important role in tumor early diagnosis and whole-
course monitoring of response to antitumor angiogenesis therapy.
Integrin is a superfamily of adhesion molecules and plays an important role in tumor 
angiogenesis and metastasis.5 Integrin αvβ3 can bind with arginine-glycine-aspartic acid 
(RGD) in an extracellular matrix (ECM). It is expressed at high density in activated 
tumor vessels and at low density in rest-stage endothelial cells.6 Although an RGD 
polypeptide target-labeled αvβ3 diagnostic probe has been developed and used in International Journal of Nanomedicine 2009:4 242
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positron emission tomography (PET),4 single photon emission 
computed tomography (SPECT), optical imaging7 and ultra-
sound imaging,8 and the radioactive tracer  18F-FDG-RGD 
target-labeled αvβ3 has been used in PET for human trials,9 
one of the inadequacies of PET monitoring is its low spatial 
resolution.4 In contrast, magnetic resonance imaging (MRI) 
not only has a higher spatial resolution but also provides 
better contrast for the soft tissues without ionizing radiation. 
Therefore, good prospects are expected in target imaging of 
angiogenesis.10 The inadequacy of MRI is its low sensitivity. 
Ultra-small superparamagnetic iron oxide (USPIO) is a new 
MRI contrast medium, mainly producing T2 negative con-
trast effect. As its unit iron can produce more signal changes, 
USPIO overcomes the disadvantage of the low sensitivity of 
conventional MRI contrast media. Zhang, a member of our 
research team, has developed a USPIO probe and coupled it 
with RGD to target and label αvβ3 receptor molecules specifi-
cally expressed in endothelial cells of tumor angiogenic blood 
vessels. The results showed that it was possible to identify the 
nature of a tumor by the degree of αvβ3 expression and the 
profile of tumor angiogenic blood vessels, thus making trace 
tumor angiogenesis much easier. In addition, it was helpful 
in judging the prognosis of the tumor detected.11 Unfortunately, 
Zhang’s USPIO probe was tried only on 1.5T MR imaging 
in vivo in a tumor model with negative αvβ3 expression. Now 
3.0T MR has been used widely in clinical practices. In addition, 
the development of coils for small animals has greatly raised 
the signal-to-noise ratio of images, which helps identify 
micro-lesions much more clearly. It is also known that αvβ3 
expression occurs not only on angiogenic blood vessels but on 
the surface of tumor cells.7 However, it is unclear whether a 
tumor model with positive αvβ3 expression would affect the 
targeting of the probe.
The  purpose  of  the  present  study  was  to  use 
3-aminopropyltrimethoxysilane (APTMS)-coated USPIO 
coupled with an integrin targeted RGD polypeptide to develop 
a nanoprobe that can bind with integrin αvβ3, and then to 
test it with a clinical 3.0T MR scanner in animal lung cancer 
models in vivo to see whether it can maintain its targeting 
in tumors with different αvβ3 expression patterns, and 
differentiate quantitatively the cumulative effects of the probe 
by T2 relaxation rate.
Materials and methods
Preparation of RgD-UsPIO nanoprobe11
All chemical materials were purchased from Sinopharm 
Chemical Reagent Co., Ltd. c(RGDfK) was purchased from 
Peptides International, Inc. (Louisville, KY, USA).
Preparation and decoration of magnetic 
nanoparticles
Magnetic nanoparticles were prepared by a chemical 
coprecipitation method.12 Appropriate amounts of FeSO4 
and FeCl3 were mixed at a 1:2 molar ratio and transferred 
to a 3-necked flask, to which an excess amount of NaOH 
solution was added gradually with mechanical agitation. 
The reaction was maintained at 60 °C for 1 hour to obtain 
Fe3O4 nanoparticles. After washing with deionized water and 
ethanol 3 times in sequence, the particles were combined with 
(3-aminopropyl)trimethoxysilane (Si (OC2H5)3C3H7NH2, 
APTMS), reacted at 70 °C for 4 hours, and finally washed 
with de-ionized water to obtain magnetic particles with an 
amino group on the surface.
coupling of RgD polypeptide
Glutaraldehyde phosphate-buffered saline (PBS) (pH 7.4) 
solution (v/v, 5%) was prepared. 50 mg APTMS-coated mag-
netic particles were diffused in 2 mL glutaraldehyde solution 
and agitated at room temperature for 4 hours. Glutaraldehyde-
activated magnetic particles were retrieved with a magnet 
and washed with PBS 3 times. 0.5 mg RGD polypeptide 
was dissolved in 0.5 mL PBS (pH 7.4). 10 mg activated 
magnetic particles were diffused in polypeptide solution and 
oscillated for 24 hours. The polypeptide-coupled magnetic 
microparticles were collected with a magnet, washed with 
PBS 3 times, diffused in 1 mL 1mol/L glycine solution, and 
sealed for 1 hour. The as-prepared probe was precipitated, 
washed and finally dispersed into PBS (pH 7.4) solution.
In vitro evaluation of specificity  
of the RgD-UsPIO probe
Relaxometry and MR imaging of labeled hUVecs
cell culture
Human umbilical vein endothelial cells (HUVECs) with posi-
tive αvβ3 receptor expression (Biosis Biotechnology Co., Ltd., 
Shanghai, China) were maintained with endothelial cell culture 
medium (199 culture solution) supplemented with 10% fetal 
bovine serum, 100 IU/mL penicillin and 100 µg/mL strepto-
mycin under 5% CO2 atmosphere at 37 °C.
HUVECs were incubated with the RGD-USPIO or plain 
USPIO at an iron concentration of 0.03 µmol/mL for differ-
ent periods of time (10 min, 30 min). After incubation, the 
culture medium was removed and the cells were washed with 
PBS (0.1 mol/L, pH 7.4) 3 times, trypsinized and suspended 
in culture medium. Cells were retrieved by centrifugation at 
2000 g for 5 min. For relaxometry and MR imaging, cells 
(2 × 106) were embedded in 400 µL 10% gel. MR imaging International Journal of Nanomedicine 2009:4 243
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was performed with a 3.0T MR scanner (GE SIGNA 
EXITE II) equipped with a mouse-imaging coil for signal 
excitation and reception with the following sequences:
T2 weighted FRFSE-XL sequence for morphology: 
TR = 3960 ms; TE = 105.2 ms; wave width 19.2 kHz; 
FOV = 10 cm; matrix = 256 × 192; thickness/interval 
2.0/0.5 mm; 4 collections).
T2* weighted gradient echo sequence for calculation 
of T2* and R2* value: TR = 120 ms; TE = 2.6–41.6 ms; 
wave width = 31.3 kHz; FOV = 8 cm; matrix = 288 × 192; 
thickness/interval 2.0/0.5 mm; 4 collections.
T2* and R2* values were automatically calculated 
by GE functional tool software package (ADW4.2 work 
platform). The mean value was obtained from calculations 
of 3 zones.
TeM study of hUVecs
For TEM study of cells, cells were incubated with the 
RGD-USPIO or plain USPIO at an iron concentration of 
0.03 µmol/mL for 10 min or 30 min. After incubation, cells 
were washed with PBS (0.1 mol/L, pH 7.4) 3 times, trypsin-
ized and retrieved by centrifugation. Then cells were fixed 
with 2.5% glutaraldehyde at 4 °C overnight, stained with 2% 
osmic acid and 0.5% uranyl acetate, and sliced into 5 µm 
sections. Micrographs were taken with a HITACHI H800 
electron microscope at 100 kV . The magnification indicator 
was routinely controlled by the use of a grating replica.
MRI detecting αvβ3 integrin in vivo
All procedures were approved by the animal center of the 
Second Military Medical University (Shanghai, China). For 
detecting αvβ3 integrin in vivo, tumor xenograft with non-
small cell lung cancer cells (3LL or A549, 5 × 105 cells, Biosis 
Biotechnology Co., Ltd Shanghai, China) were implanted 
into the left armpit of Bal/C mice. When tumors reached 1 cm, 
the RGD-USPIO or plain USPIO were used to inject the mice 
(six 3LL mice and five A549 mice respectively) at a dose of 
100 µmol Fe/kg through the tail vein. After injection, MR 
imaging was performed with a 3.0T MR scanner (GE SIGNA 
EXITE II) with the following sequences:
T2 weighted FRFSE-XL sequence for morphology: 
TR = 3960 ms; TE = 105.2 ms; wave width = 19.2 kHz; 
FOV = 10 cm; matrix = 256 × 192; thickness/interval 
2.0/0.5 mm; 4 collections.
T2* weighted gradient echo sequence for calculation of 
T2* value and R2* value: TR = 120 ms; TE = 2.6–41.6 ms; 
wave width = 31.3 kHz; FOV = 8 cm; matrix = 288 × 192; 
thickness/interval 2.0/0.5 mm; 4 collections.
T2* and R2* values of the tumor, blood, liver, kidney, 
heart and muscle before and after probe injection were auto-
matically calculated by GE functional tool software package 
(ADW4.2 work platform). Pseudo-olor images of MR R2* 
values also were delineated by the same software. The mean 
value was obtained from calculations of 3 zones.
hematoxylin and eosin (he) stain 
and immunohistochemistry
streptavidin-perosidase (sP) staining of tumor cells
Cells were plated in 6-chamber plates (Biosis Biotechnology 
Co., Ltd., Shanghai, China) at a concentration of 2 × 104 cells/
well. When cell growth was 80% confluent, the cell was 
fixed with paraformaldehyde (v/v, 4%). For SP staining, 
3LL or A549 lung cancer cell (murine cells) was first incu-
bated with hamster antimouse CD61 (β3) primary antibody 
(1:100 dilution) at 4 °C overnight, then with biotin-labeled 
antihamster secondary antibody (1:100 dilution) at room 
temperature for 30 min. After washing with PBS 3 times, 
100 µL (1:200 dilution) streptavidin-coupled horseradish 
peroxidase (streptavidin-HRP) was added and incubated at 
room temperature for 20 min, followed by adding freshly 
prepared 0.01% diaminobenzidine with 5–10 min incubation. 
The reaction was terminated by washing with distilled water 
3 times. Cells were counterstained with hematoxylin-esoin 
and returned to blue with ammonia water. After drying with 
gradient alcohol and xylene, cells were mounted with 50% 
glycerine.
he, sP staining of tumor tissues
After MR imaging, the mouse were sacrificed and the sub-
cutaneous tumor tissue was removed completely and fixed 
with glutaraldehyde at 4 °C overnight, paraffin-embedded, 
and sliced into 4 µm sections.
For HE staining, the sections were dewaxed with xylene 
and washed with ethanol and water successively. After hema-
toxylin staining for 5 min, the sections were washed with 
distilled water, differentiated with ethanol for 30 sec and 
soaked for 5 min in 50 °C water, followed by conterstaining 
with eosin solution for 2 min.
For SP staining, the sections were heated in a microwave 
oven to maintain the temperature at 92–98 °C for 10–15 min 
for antigen retrieval, then incubated with 10% normal 
goat serum. For tumor tissue SP staining, the procedure 
was the same as that for tumor cell SP staining described 
above. After staining, the sections were dehydrated with 
gradient ethanol, hyalinized with xylene, then mounted 
on the slip.International Journal of Nanomedicine 2009:4 244
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statistical analysis
The Wilcoxon rank sum test was used for statistical evaluation. 
P  0.05 was considered statistically significant.
Results
charactierization of RgD-UsPIO probe
TEM examination indicated that the size of nano-Fe3O4 
particles was 10 ± 2 nm, and did not undergo significant 
change after modification (Figure 1). The coating was 
manifested by inductively coupled mass spectrometry; 
iron and silicon contents were 68.83 wt% and 1.316 wt%, 
respectively. Organic element analysis further indicated 
that the contents of carbon, hydrogen and nitrogen were 
3.56 wt%, 1.22 wt% and 1.50 wt%, respectively. T2 and T1 
relaxivity values of RGD-UAPIO were 114.9 and 10.64 s−1 
(mmol/L)−1.
Specificity study of RGD-USPIO 
probe in vitro
The specificity of the RGD-USPIO probe for αvβ3 integrin 
was examined by relaxometry measurement and MR imag-
ing of HUVECs cells (Figure 2). The T2* value of cells was 
193.22 ± 10.71 ms after incubation with the RGD-USPIO 
probe at an iron concentration of 0.03 µmol/mL for 10 min, 
which decreased to 182.58 ± 8.94 ms after 30 min incubation. 
For the control cells (cells incubated with plain USPIO with 
the same iron concentration), the T2* value was 206.64 ± 9.69 
ms, even after incubation for 30 min, significantly different 
from the decrease in the T2* with the RGD-USPIO probe 
(P  0.05).
Consistent with relaxometry measurement, co-culture of 
HUVECs with plain USPIO or RGD-USPIO both reduced 
signal intensity (Figure 2B). However, compared with the 
control cells, after incubation for 10 min the decrease in 
signal intensity for cells incubated with RGD-USPIO was 
heterogeneous and much more pronounced. After 30 min 
co-culture with RGD-USPIO, the reduction in signal intensity 
was even more evident.
TEM images of cells co-cultured with RGD-USPIO or 
plain USPIO are shown in Figure 3, which shows that a 
certain amount of the RGD-USPIO probe was already inter-
nalized by endothelial cells after 10 min co-culture, and even 
more RGD-USPIO after 30 min co-culture. In the control 
group, the plain USPIO probe was mainly distributed outside 
endothelial cells, with only a small number of particles being 
attached to the cell membrane.
In vivo imaging of αvβ3 expression
SP staining indicated the different expression patterns of 
αvβ3 integrin in A549 and 3LL tumor cells (Figure 4). For 
the A549 cell line, αvβ3 integrin was expressed mainly on 
the cell membrane and partially on endochylema. For 3LL 
cells, no αvβ3 expression was found.
T2*-weighted MR images showed that after the 
administration of the RGD-USPIO probe, the reduction 
Figure 1 Transmission electron microscopy (TeM) picture of RgD-UsPIO nanoparticles. 
TeM examination indicated that the size of RgD-UsPIO particles was 10 ± 2 nm.
Abbreviations: RgD-UsPIO, arginine-glycine-aspartic acid peptide conjugated ultra-
small superparamagnetic iron oxide nanoparticles (RgD-UsPIO).
Figure 2 cell suspended in gel A) and magnetic resonance imaging of the cells 
B) after co-cultured with RgD-UsPIO for 30 min (left) and 10 min (middle) or plain 
UsPIO (right) for 30 min.  compared with control, more RgD-UsPIO was internalized 
by hUVecs, leading to a darker color and pronounced MRI signal intensity decrease 
of cells incubated with RgD-UsPIO. Moreover, cell uptake of RgD-UsPIO increased 
with increase of incubation time.
Abbreviations: hUVecs, human umbilical vein endothelial cells; RgD-UsPIO, 
arginine-glycine-aspartic acid peptide conjugated ultra-small superparamagnetic iron 
oxide nanoparticles (RgD-UsPIO).International Journal of Nanomedicine 2009:4 245
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of signal intensity in 3LL tumor was distributed mainly 
in the periphery and some central areas of the tumor. 
This observation was more vividly reflected by pseudo-
color images of MR R2* values: the intense orange 
surrounding the tumor indicates the increase of R2* 
value on the periphery of the tumor, corresponding to the 
decrease of signal intensity. In contrast, signal reduction 
was not significantly different on both MR images of the 
tumor after administration of plain USPIO (Figure 5). 
Consistent with MR imaging, the difference in R2* value 
of tumors after and before injection of the RGD-USPIO 
probe was 84.16 ± 13.00 s−1, compared with 18.82 ± 
4.42 s−1 (P  0.05) for tumors receiving plain USPIO 
(Figure 6). Microscopically, the angiogenic blood vessels 
were displayed mainly in the periphery and some central 
areas of 3LL tumor, and SP staining showed that the 
neoveculature was αvβ3 positive (Figure 4).
In contrast to 3LL tumor, reduction of signal intensity 
in T2*-weighted images after the administration of the 
RGD-USPIO probe in the A549 tumor model was homo-
geneous and a reduced signal intensity was observed in 
the periphery of and inside the tumor. Moreover, the area 
of increased R2* value reflected by pseudo-color pictures 
was seen throughout the tumor and was more evident in 
the periphery or central areas. After plain USPIO injection, 
no significant signal reduction could be found (Figure 5). 
R2* value increased significantly after injection of the 
RGD-USPIO probe (101.74 ± 6.27 s−1) compared with that 
of the plain USPIO group (24.46 ± 4.45 s−1) (P  0.05) 
(Figure 6). For histological study, HE staining was simi-
lar to that of 3LL lung cancer, and the angiogenic blood 
vessels were seen mainly in the periphery of the tumor. 
However, both vascular endothelial and tumor cells were 
αvβ3 integrin positive (Figure 4).
The injection of the RGD-USPIO also induced the 
reduction of T2* value of other organs, such as liver, kidney 
and muscle, most significantly in the liver (Figure 6).
Discussion
Although clinically available MR contrast media and various 
probes for detecting angiogenesis are able to enhance 
T1 positive signals,13–15 negative contrast is still compara-
tively advantageous because USPIO produces a reduction 
effect of T2 relaxation time, which can be enhanced by the 
magnetic-sensitive effect of gradient echo sequence, thus 
producing excess voxel and enhancing MR sensitivity at 
the same time.16 It has been documented that this magnetic-
sensitive effect is more evident in 3.0T magnetic field than 
in 1.5T magnetic field.17
The present study attempts to evaluate the expression 
of αvβ3 integrin in different lung cancer models in vivo 
by observing binding of the RGD-USPIO probe with αvβ3 
with a 3.0T MR scanner by using APTMS-coated USPIO 
coupling with RGD polypeptide. The merit of coating the 
probe with ATPMS is that in addition to the amino groups 
being exposed on the surface of the particles, and thus 
able to couple with specific ligands covalently, the coat-
ing layer can be made very thin without inducing any MR 
signal loss under the encapsulation.18 This is important to 
maintain the nano-class diameter of the particles. Gener-
ally, the smaller the diameter of the probe, the better the 
pharmacokinetics. In addition, such a probe usually has 
better extravasation and binding ability with the target after 
coupling with specific ligands.19,20 The RGD polypeptide 
Figure 3 Transmission electron microscopy images of hUVecs co-cultured with RgD-UsPIO for 10 min A) and 30 min B) or UsPIO for 30 min C) at the iron concentration 
of 0.03 µmol/mL.   A certain amount of RgD-UsPIO probe was ready internalized by the cells 10 min after co-culture and even more after 30 min co-culture. In contrast, the 
plain UsPIO probe was distributed mainly outside endothelial cells, with only a small number of particles attached to the cell membrane.
Abbreviations: hUVecs, human umbilical vein endothelial cells; RgD-UsPIO, arginine-glycine-aspartic acid peptide conjugated ultra-small superparamagnetic iron oxide 
nanoparticles (RgD-UsPIO).International Journal of Nanomedicine 2009:4 246
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used in the present study is a commercial available cyclo 
RGD (c(RGDfK)), whose stability is 30 times more than 
that of linear RGD.21 Zhang et al has used a similar method 
to perform MRI. The results showed that it was possible 
to identify the nature of the tumor through the degree 
of αvβ3 expression and the profile of tumor angiogenic 
blood vessels, thus making tracing of tumor angiogenesis 
much easier.11
However, we cannot exclude the possibility of some RGD 
peptides coupling with the activated USPIO through the 
amino group of arginine in RGD peptide at the active binding 
sites, which may impair specificity of the probe. For this 
Figure 4 he and sP staining of tumor cells  (A, B) or tumor tissues (C–F).   The different expression patterns of αvβ3 integrin were shown by sP staining. For 3LL cells, there 
was no αvβ3 expression found A). For A549 cell line, αvβ3 integrin was expressed mainly on the cell membrane and partially on endochylema (B arrow), Microscopically, 
the newborn vessels were displayed mainly in the periphery and some central areas of 3LL tumor in he staining C), and sP staining showed that the neoveculature was αvβ3 
positive E). For A549 histological study, he staining was similar to that of 3LL lung cancer and the newborn vessels were seen mainly in the periphery of the tumor D). Both 
vascular endothelial and tumor cells were αvβ3 expression positive F). There was no apparent difference in distribution of newborn vessels and necrosis in the pathological 
sections.
Abbreviations: he, hematoxylin and eosin; sP, streptavidin-peroxidase.International Journal of Nanomedicine 2009:4 247
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reason, we conducted the in vitro experiment and found that 
the RGD-USPIO was able to bind to HUVECs specifically, 
and that this binding ability was receptor-mediated (cell) 
endocytosis. MR examination of the cell gel suspension 
showed that the MR signal intensity decrease of HUVECs 
co-cultured with the RGD-coupled USPIO probe was much 
more significant than that of HUVECs incubated with the 
plain USPIO probe, confirming the unimpaired specificity 
of the RGD-USPIO probe.
We also observed characteristic MR signal changes of 
αvβ3 expression in different tumor models on T2* and R2* 
pseudo-color pictures after RGD-USPIO injection in mice, 
and differentiated the accumulative effect of the probe by T2* 
quantification. It was found that RGD-USPIO caused hetero-
geneous signal reduction in 3LL lung cancer mice mainly 
in the periphery and a few central areas of the tumor, which 
is consistent with the type of tumor angiogenesis and the 
pattern of integrin expression confirmed by the histological 
study of the tumor tissue. This also agrees with previous 
findings in αvβ3-negative tumors.11 In tumor-bearing mice 
injected with USPIO alone, there was only a slight change in 
background signals on MR images, probably due to extrava-
sation of particles from tumor vessels and dissemination to 
intercellular space.22
However, we found that the probe distribution pattern 
on T2*-weighted MR imaging of A549 lung cancer mice 
with positive αvβ3 expression on tumor cells was different 
from that in 3LL lung cancer mice with negative αvβ3 
expression on tumor cells. For A549 tumors, low signal 
areas were in both the periphery of and inside the tumor, 
but more prominent in the periphery. T2 relaxation times 
of the two tumors were significantly lower than that of the 
USPIO control group, though the difference between these 
tumors was not statistically significant. We first exclude the 
possibility of heterogeneity of angiogenesis due to differ-
ent sizes of the two tumors, because there is no significant 
difference in the microvessel density between tumors with 
a size of 1 cm.23 Thus, the possibility that the differences 
might be related to the tumor development of the necrosis 
areas is also excluded. It is true that a tumor with a size of 
1 cm might have necrosis, but there was no apparent differ-
ence between the two type of lung cancer in the pathological 
sections. The possible explanation is that this difference is 
related to αvβ3 expression. Immunohistochemistry showed 
that for the A549 tumor, CD61 is not only expressed in 
angiogenic blood tumor vessels but also in tumor cells 
around the vessels. Therefore, it is reasonable to speculate 
that part of the RGD-USPIO probes extravasate from tumor 
vessels and bind with tumor cells due to the loose connection 
between endothelial cells of angiogenic blood vessels.24 So, 
this different enhancement pattern in MR imaging of dif-
ferent tumor may not only be related to the profile of tumor 
angiogenic blood vessels, but may also involve specific 
binding between the RGD-USPIO and tumor cells.25 Thus, 
tumor cells would interfere with the targeting of the probe 
to angiogenic blood vessels. This will make it difficult to 
evaluate in vivo angiogenesis of tumors with positive αvβ3 
expression and to detect the effects of antiangiogenesis 
therapies. Indeed, this question cannot be answered by the 
preliminary results obtained in a small number of animals 
in the present study. Especially, the in vivo experiments are 
challenging because the RGD-USPIO cannot reach tumor 
cells easily (due to their short circulation time). In addition, 
evaluation of MR targeting in vivo cannot not be as accurate 
as immunohistochemical staining of tumor tissue, because 
the marker is less sensitive. Another reason is that vari-
ous conditions in vivo (such as water buffering or plasma 
buffering) may affect detection of the relaxation rate, 
causing overestimation of local concentrations in vivo.26
Whether the contrast medium could be transported to the 
target is also a difficult problem due to nonspecific phago-
cytosis of macrophages.27 Most probes are absorbed by the 
liver and reticular endothelial system, whose uptake may 
even exceed that in tumor areas, which makes it difficult to 
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Figure 5 Pseudo-color magnetic resonance (MR) images of tumors after the 
injection of RgD-UsPIO A) and T2-weighted MR images of tumor after the injection 
of UsPIO B) Pseudo color MR images reflected the reduction of signal intensity in 
3LL tumor mainly distributed in the periphery and some central areas of the tumor 
after the administration of RgD-UsPIO probe. Different from 3LL tumor, for A549 
tumor, the area of increased R2* value was seen throughout the tumor and more 
evident in the periphery or central areas A). In contrast, signal reduction was not 
significantly different after administration of plain USPIO on both MR images of 3LL 
and A549 tumor B).
Abbreviation: RgD-UsPIO, arginine-glycine-aspartic acid peptide conjugated ultra-
small superparamagnetic iron oxide nanoparticles (RgD-UsPIO).International Journal of Nanomedicine 2009:4 248
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study location and characterization of angiogenesis during 
metastasis in these organs.
Conclusion
Despite these problems, the results available have shown that 
the RGD-USPIO probe can specifically bind with endothelial 
cells of angiogenic blood vessels. Therefore, it is possible to 
delineate tumor angiogenesis and use the probe to monitor 
noninvasively change of angiogenesis during tumor therapy 
with the clinical 3.0T MR scanner. Although the targeting 
pattern of the probe is different in tumors with different αvβ3 
expressions, it is envisioned that MRI molecular imaging of 
target angiogenic blood vessels has a good future.28,29 First, 
it is a noninvasive monitoring method and would not affect 
tissue integrity. Second, it can detect the whole tumor and it is 
unnecessary to do tissue biopsy from one or more sites. Third, 
it is possible to monitor the tumor status or therapeutic effects 
in a quantitative real-time manner. Our future research will 
focus on seeking more specific target points and optimizing 
pharmacokinetic behaviors of the probe.
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Figure 6 change in R2* value of tumors A) and T2* value of organs B) after administration of RgD-UsPIO or plain UsPIO.   The difference in R2* value of 3LL tumor before 
and after injection of the RgD-UsPIO probe was 84.16 ± 13.00 s−1, compared with 18.82 ± 4.42 s–1 for tumors receiving plain UsPIO (*P  0.05). similarily, R2* value increased 
significantly after injection of RGD-USPIO probe (101.74 ± 6.27 s−1) compared with that of the plain UsPIO group (24.46 ± 4.45 s−1) in   A549 tumor A)  T2* value of all the 
organs decreased after injection of RGD-USPIO or USPIO; however, there was no significant difference between the two probes B).
Abbreviation: RgD-UsPIO, arginine-glycine-aspartic acid peptide conjugated ultra-small superparamagnetic iron oxide nanoparticles (RgD-UsPIO).International Journal of Nanomedicine 2009:4
International Journal of Nanomedicine
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-nanomedicine-journal
The International Journal of Nanomedicine is an international, peer-
reviewed journal focusing on the application of nanotechnology 
in diagnostics, therapeutics, and drug delivery systems throughout 
the biomedical field. This journal is indexed on PubMed Central, 
MedLine, CAS, SciSearch®, Current Contents®/Clinical Medicine, 
Journal Citation Reports/Science Edition, EMBase, Scopus and the 
Elsevier Bibliographic databases. The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
249
characterizing αvβ3 expression patterns in lung cancers Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
13.  Taupitz M, Schnorr J, Abramjuk C, et al. New generation of 
monomer-stabilized very small superparamagnetic iron oxide particles 
(VSOP) as contrast medium for MR angiography: preclinical results in 
rats and rabbits. J Magn Reson Imaging. 2000;12(6):905–911.
14.  Kiessling F, Heilmann M, Vosseler S, et al. Dynamic T1-weighted 
monitoring of vascularization in human carcinoma heterotransplants 
by magnetic resonance imaging. Int J Cancer. 2003;104(1):113–120.
15.  Geninatti Crich, Simonetta, Benedetta Bussolati, et al. Magnetic 
resonance visualization of tumor angiogenesis by targeting neural 
cell adhesion molecules with the highly sensitive gadolinium-loaded 
apoferritin probe. Cancer Res. 2006;66(18):9196–9201.
16.  Peeters JM, Seppenwoolde JH, Bartels LW, Bakker CJ. Development 
and testing of passive tracking markers for different field strengths and 
tracking speeds. Phys Med Bio. 2006;51(6):127–137.
17.  Soher BJ, Dale BM, Merkle EM. A review of MR physics: 3T 
versus 1.5T. Magn Reson Imaging Clin N Am. 2007;15(3):277–290.
18.  Kohler N, Fryxell GE, Zhang M. A bifunctional poly(ethylene glycol) 
silane immobilized on metallic oxide-based nanoparticles for con-
jugation with cell targeting agents. J Am Chem Soc. 2004;126(23): 
7206–7211.
19.  Bruce IJ, Sen T. Surface modification of magnetic nanoparticles 
with alkoxysilanes and their application in magnetic bioseparations. 
Langmuir. 2005;21(15):7029–7035.
20.  Sun EY, Josephson L, Kelly KA, Weissleder R. Development of nanopar-
ticle libraries for biosensing. Bioconjug Chem. 2006;17(1):109–113.
21.  Bogdanowich-Knipp SJ, Chakrabarti S, Williams TD, Dillman RK, 
Siahaan TJ. Solution stability of linear vs cyclic RGD peptides. J Pept 
Res. 1999;53(5):530–541.
22.  Mulder WJ, Strijkers GJ, Habets JW, et al. MR molecular imaging and 
fluorescence microscopy for identification of activated tumor endo-
thelium using a bimodal lipidic nanoparticle. FASEB J. 2005;19(14): 
2008–2010.
23.  Jackson, Alan, James PB, O'Connor, et al. Imaging tumor vascular het-
erogeneity and angiogenesis using dynamic contrast-enhanced magnetic 
resonance imaging. Clin Cancer Res. 2007;13(12):3449–3459.
24.  Raatschen HJ, Fu Y, Sennino B, et al. Vascular permeability during 
antiangiogenesis treatment: MR imaging assay results as biomarker for 
subsequent tumor growth in rats. Radiology. 2008;247(2):391–399.
25.  Achilefu S, Bloch S, Markiewicz MA, et al. Synergistic effects of 
light-emitting probes and peptides for targeting and monitoring integrin 
expression. Proc Natl Acad Sci U S A. 2005;102(22):7976–7981.
26.  Tang Y, Minjung K, Daniel C, et al. In vivo assessment of RAS-
dependent maintenance of tumor angiogenesis by real-time magnetic 
resonance imaging. Cancer Res. 2005;65(18):8324–8330.
27.  Raynal I, Prigent P, Peyramaure S, et al. Macrophage endocytosis 
of superparamagnetic iron oxide nanoparticles: mechanisms and 
comparison of ferumoxides and ferumoxtran-10. Invest Radiol. 2004; 
39(1):56–63.
28.  Winter PM, Caruthers SD, Kassner A, et al. Molecular imaging of angio-
genesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-
targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer 
Res. 2003;63(18):5838–5843.
29.  Oostendorp M, Kim D, Tilman M, et al. Quantitative molecular mag-
netic resonance imaging of tumor angiogenesis using cNGR-labeled 
paramagnetic quantum dots. Cancer Res. 2008;68(18):7676–7683.